Ki-67, the chromosome periphery and de-compartmentalisation each contribute to nucleophosmin mislocalisation in acute myeloid leukaemia
Abstract
The mitotic chromosome periphery (MCP) is an important chromosome compartment but links to disease remains elusive. Here we define the mitosis-specific, Ki-67 interactome, identifying additional MCP components and revealing that MCP genes are commonly mutated in cancer, including nucleophosmin (NPM1). Acute myeloid leukaemia (AML)-specific NPM1 mutations (NPM1c + ), result in protein mislocalisation (nucleolus to cytoplasm). We demonstrate that NPM1c+ fails to adequately bind to the MCP, instead forming aggregates during mitosis. We also report that, de-compartmentalisation at mitotic onset allows formation of NPM1wt/c+ multimers. These mislocalisation mechanisms contribute to a significant hinderance of NPM1 re-entry into daughter cell nucleoli. Enhancing MCP loading capacity via Ki-67 overexpression resulted in increased MCP-bound NPM1c+ during mitosis and greater yield of nucleolar NPM1c + . Ki-67 expression demonstrated a significant interaction with NPM1 mutation status on AML patient overall survival, whereby higher Ki-67 was associated with increased hazard in NPM1wt but reduced hazard in NPM1c+ patients. This work reveals mechanistic insight into AML and evidence that the MCP has untapped therapeutic potential.
Related
- Compartmentalisation of death receptor signalling in cancer
- Inverted logic of ecDNA localization converts nuclear periphery into oncogenic transcription hubs in cancer
- The cGAS-STING Pathway in Neuroinflammation and Neurological Disease: Mechanisms, Disease Contexts, and Periphery-to-Brain Communication
- Do Grape- and Wine-Derived (Poly)Phenols Contribute to the Hallmarks of Healthy Brain Ageing?
- Gpnmb-positive lipid-associated macrophages contribute to lipid clearance during luteolysis
BibTeX
@article{grundy2026ki67,
title = {{Ki-67, the chromosome periphery and de-compartmentalisation each contribute to nucleophosmin mislocalisation in acute myeloid leukaemia}},
author = {Martin Grundy and Peter Woodmancy and Kellie Lucken and Xiaomeng Xing and Robert Markus and Seema Bagia and Sarah Storr and Claire H. Seedhouse and Daniel G. Booth},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/s41467-026-78560-3},
url = {https://www.nature.com/articles/s41467-026-78560-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ki-67, the chromosome periphery and de-compartmentalisation each contribute to nucleophosmin mislocalisation in acute myeloid leukaemia
AU - Martin Grundy
AU - Peter Woodmancy
AU - Kellie Lucken
AU - Xiaomeng Xing
AU - Robert Markus
AU - Seema Bagia
AU - Sarah Storr
AU - Claire H. Seedhouse
AU - Daniel G. Booth
PY - 2026
DA - 2026/10/12
JO - Nature Communications
DO - 10.1038/s41467-026-78560-3
UR - https://www.nature.com/articles/s41467-026-78560-3
AB - The mitotic chromosome periphery (MCP) is an important chromosome compartment but links to disease remains elusive. Here we define the mitosis-specific, Ki-67 interactome, identifying additional MCP components and revealing that MCP genes are commonly mutated in cancer, including nucleophosmin (NPM1). Acute myeloid leukaemia (AML)-specific NPM1 mutations (NPM1c + ), result in protein mislocalisation (nucleolus to cytoplasm). We demonstrate that NPM1c+ fails to adequately bind to the MCP, instead forming aggregates during mitosis. We also report that, de-compartmentalisation at mitotic onset allows formation of NPM1wt/c+ multimers. These mislocalisation mechanisms contribute to a significant hinderance of NPM1 re-entry into daughter cell nucleoli. Enhancing MCP loading capacity via Ki-67 overexpression resulted in increased MCP-bound NPM1c+ during mitosis and greater yield of nucleolar NPM1c + . Ki-67 expression demonstrated a significant interaction with NPM1 mutation status on AML patient overall survival, whereby higher Ki-67 was associated with increased hazard in NPM1wt but reduced hazard in NPM1c+ patients. This work reveals mechanistic insight into AML and evidence that the MCP has untapped therapeutic potential.
SN - 2041-1723
ER -